Evidence map›Paper›PMID 25060052›Full record

ArticleJournal of the American Society of Nephrology : JASN2015

Serum fibroblast growth factor-23 is associated with incident kidney disease.

Casey M Rebholz, Morgan E Grams, Josef Coresh, Elizabeth Selvin, Lesley A Inker, Andrew S Levey, Paul L Kimmel, Ramachandran S Vasan, John H Eckfeldt, Harold I Feldman and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Fibroblast growth factor 23 and incident CKD in type 2 diabetes.Clinical journal of the American Society of Nephrology : CJASN · 2015
    Trial
  4. Article
  5. Fibroblast Growth Factor 23, Urinary Phosphate, and Risk of Progression of CKD.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Association Between Ultraprocessed Food Consumption and Risk of Incident CKD: A Prospective Cohort Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2022
    Article
  14. Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic.International journal of molecular sciences · 2022
    Review
  15. Article
  16. Article
  17. Observational
  18. How FGF23 shapes multiple organs in chronic kidney disease.Molecular and cellular pediatrics · 2021
    Review
  19. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2021
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Casey M RebholzDepartment of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; crebhol1@jhu.edu.
Morgan E GramsDepartment of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Divisions of Nephrology and.
Josef CoreshDepartment of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; General Internal Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland;
Elizabeth SelvinDepartment of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; General Internal Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland;
Lesley A InkerWilliam B. Schwartz Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts;
Andrew S LeveyWilliam B. Schwartz Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts;
Paul L KimmelNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland;
Ramachandran S VasanSections of Preventive Medicine and Epidemiology and Cardiology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts;
John H EckfeldtDepartment of Laboratory Medicine and Pathology, University of Minnesota School of Medicine, Minneapolis, Minnesota;
Harold I FeldmanDepartments of Biostatistics and Epidemiology, and Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania;
Chi-Yuan HsuDivision of Nephrology, Department of Medicine, University of California, San Francisco School of Medicine, San Francisco, California; and.
Pamela L LutseyDivision of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, Minnesota.
Chronic Kidney Disease Biomarkers Consortium
Johns Hopkins University · USTufts Medical Center · USUniversity of Minnesota · USBoston University · USNational Institutes of Health · USUniversity of California, San Francisco · USUniversity of Pennsylvania · US

Funding

CARDIOVASCULAR EPIDEMIOLOGY INSTITUTIONAL TRAININGT32HL007024 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Elizabeth Selvin · 1985 to 2026
$17.5M
Diabetes and Prediabetes in Older Adults in ARICR01DK089174 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI SELVIN, ELIZABETH · 2011 to 2020
$6.4M
Proteomic Approach to CKD Biomarker Discovery and ValidationU01DK085689 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI CORESH, JOSEF · 2009 to 2019
$5.6M
Urinary Biomarkers of Chronic Kidney Disease Pathology and ProgressionU01DK085660 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT, WAIKAR, SUSHRUT S. · 2009 to 2019
$5.3M
"Validation of Novel CKD Biomarkers in CRIC"U01DK085649 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, CHI-YUAN, LIU, KATHLEEN D · 2009 to 2013
$4.4M
The New York CKD Biomarker Discovery ProgramU01DK085688 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BOTTINGER, ERWIN P. · 2009 to 2013
$3.0M
Serum Vitamin D and Cardiovascular Disease Risk in the Biethnic ARIC CohortR01HL103706 · NHLBI · UNIVERSITY OF MINNESOTA · PI LUTSEY, PAMELA L. · 2011 to 2014
$2.3M
Urinary Biomarkers in Biopsy Defined Early Nephropathy in Types 1 and 2 DiabetesU01DK085651 · NIDDK · UNIVERSITY OF MINNESOTA · PI MAUER, S. MICHAEL · 2009 to 2013
$2.2M
Forecasters of futute and progressive CDK in patients with microvascular glomerulU01DK085673 · NIDDK · OHIO STATE UNIVERSITY · PI KLEIN, JON, ROVIN, BRAD H · 2009 to 2013
$2.0M
NHLBI NIH HHS HHSN268201100005CNHLBI NIH HHS HHSN268201100005GNHLBI NIH HHS HHSN268201100005INHLBI NIH HHS HHSN268201100006CNHLBI NIH HHS HHSN268201100007CNHLBI NIH HHS HHSN268201100007INHLBI NIH HHS HHSN268201100008CNHLBI NIH HHS HHSN268201100008INHLBI NIH HHS HHSN268201100009CNHLBI NIH HHS HHSN268201100009INHLBI NIH HHS HHSN268201100010CNHLBI NIH HHS HHSN268201100011CNHLBI NIH HHS HHSN268201100011INHLBI NIH HHS HHSN268201100012CNHLBI NIH HHS R01 HL103706NHLBI NIH HHS R01-HL103706NHLBI NIH HHS T32 HL007024NHLBI NIH HHS T32-HL007024NIDDK NIH HHS R01 DK089174NIDDK NIH HHS R01-DK089174NIDDK NIH HHS U01 DK085649NIDDK NIH HHS U01-DK085649NIDDK NIH HHS U01 DK085651NIDDK NIH HHS U01-DK085651NIDDK NIH HHS U01 DK085660NIDDK NIH HHS U01-DK085660NIDDK NIH HHS U01 DK085673NIDDK NIH HHS U01-DK085673NIDDK NIH HHS U01 DK085688NIDDK NIH HHS U01-DK085688NIDDK NIH HHS U01 DK085689NIDDK NIH HHS U01-DK085689
6 · The paper itself

Abstract

Fibroblast growth factor-23 is a bone-derived hormone that increases urinary phosphate excretion and inhibits hydroxylation of 25-hydroxyvitamin D. Recent studies suggest that fibroblast growth factor-23 may be an early biomarker of CKD progression. However, its role in kidney function decline in the general population is unknown. We assessed the relationship between baseline (1990-1992) serum levels of intact fibroblast growth factor-23 and incident ESRD in 13,448 Atherosclerosis Risk in Communities study participants (56.1% women, 74.7% white) followed until December 31, 2010. At baseline, the mean age of participants was 56.9 years and the mean eGFR was 97 ml/min per 1.73 m(2). During a median follow-up of 19 years, 267 participants (2.0%) developed ESRD. After adjustment for demographic characteristics, baseline eGFR, traditional CKD risk factors, and markers of mineral metabolism, the highest fibroblast growth factor-23 quintile (>54.6 pg/ml) compared with the lowest quintile (<32.0 pg/ml) was associated with risk of developing ESRD (hazard ratio, 2.10; 95% confidence interval, 1.31 to 3.36; trend P<0.001). In a large, community-based study comprising a broad range of kidney function, higher baseline fibroblast growth factor-23 levels were associated with increased risk of incident ESRD independent of the baseline level of kidney function and a number of other risk factors.

Indexed as

Gene Expression RegulationAdultAgedAge FactorsAtherosclerosisCohort StudiesDisease ProgressionFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsGlomerular Filtration RateHumansKidney DiseasesMaleMiddle AgedRisk Factors25-hydroxyvitamin DFibroblast Growth Factor-23Fibroblast Growth FactorsVitamin DESRDmineral metabolismrisk factors

Identifiers

PMID25060052
PMCPMC4279743
OpenAlexW2160390258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.